Esophagus to Small Intestine
Am J Gastroenterol. 2024;119(5):965–76
Epidemiology, comorbidities, and treatment of cyclic vomiting syndrome in the United States
Introduction: Cyclic vomiting syndrome (CVS) imposes a substantial burden, but epidemiological data are scarce. This study aimed to estimate the incidence and prevalence of CVS, comorbid conditions, and treatment patterns, using administrative databases in the United States.
Methods: This cross-sectional study used claims data from Merative MarketScan Commercial/Medicare Supplemental and Medicaid databases in all health care settings. Incidence and prevalence rates for 2019 were calculated and stratified by age, sex, region, and race/ethnicity. Patient characteristics were reported among newly diagnosed patients with CVS (i.e., no documented claims for CVS before 2019). CVS was defined as having at least 1 inpatient and/or at least 2 outpatient CVS claims that were at least 7 days apart.
Results: The estimated prevalence of CVS was 16.7 (Commercial/Medicare) and 42.9 (Medicaid) per 100,000 individuals. The incidence of CVS was estimated to be 10.6 (Commercial/Medicare) and 26.6 (Medicaid) per 100,000 individuals. Both prevalence and incidence rates were higher among female individuals (for both Commercial/Medicare and Medicaid). Comorbid conditions were common and included abdominal pain (56–64%), anxiety (32–39%), depression (26–34%), cardiac conditions (39–42%), and gastroesophageal reflux disease (30–40%). Despite a diagnosis of CVS, only 32–35% had prescriptions for prophylactic treatment and 47–55% for acute treatment within the first 30-day period following diagnosis.
Discussion: This study provides the first population-level estimates of cyclic vomiting syndrome (CVS) incidence and prevalence in the United States. Comorbid conditions are common, and most patients with CVS do not receive adequate treatment. These findings underscore the need for improving disease awareness and developing better screening strategies and effective treatments.